Pharmaceutical · Fiscal year end Mar 31

JCR Pharmaceuticals Co.,Ltd.

4552

ＪＣＲファーマ株式会社

FIGI BBG000BBW8274552.T4552 JPCorp. no. 6140001000905

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-14

For the first half of the fiscal year to 2026-03: Revenue ¥21.4 billion (+28.2% YoY), Ordinary income ¥2.4 billion, Net income ¥1.7 billion.

	This period	Year on year
Revenue	¥21.4bn	+28.2%
Ordinary profit	¥2.4bn	—
Net profit to owners	¥1.7bn	—

From the securities report on EDINET, which states no forecast. History via /v1/companies/4552/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31

Revenue: ¥40.3bn
Net income: ¥2.2bn
ROE: 4.6%
Equity ratio: 42.9%
Dividend / share: ¥20
Employees: 985

Revenue · ¥bn

Net income · ¥bn

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2026-03-31	¥40.3bn	¥2.2bn	¥109.2bn	¥47.4bn	4.6%	¥17.87	−¥0.1bn
2025-03-31	¥33.1bn	−¥4.5bn	¥104.8bn	¥47.7bn	-8.7%	¥-36.02	−¥5.8bn
2024-03-31	¥42.9bn	¥5.5bn	¥102.2bn	¥56.5bn	10.3%	¥44.13	¥9.3bn
2023-03-31	¥34.3bn	¥3.8bn	¥94.9bn	¥52.4bn	7.4%	¥30.35	−¥5.5bn
2022-03-31	¥51.1bn	¥14.5bn	¥97.1bn	¥51.1bn	32.9%	¥117.26	¥9.3bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31

Metric	Value	Percentile among listed companies
ROE, %	4.6	22.5
Ordinary margin	0.0289	23.3
Equity ratio, %	42.9	31.1
Revenue growth	0.2191	88.7
Net income growth	1.4883	90
Operating cash flow / assets	-0.0012	16

Policy-uncertainty measure0.00 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 1.7% held by other listed companies.

Results wording balance: +0.07. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥53.9bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥269m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4552/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2026-06-23: see filing 上記の評価の結果、当連結会計年度末日において、当社グループの財務報告に係る内部統制は有効であると判断いたしました。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Latest voting result: 2026-06-23 · 取締役12名選任の件 · passed. /v1/companies/4552/voting

Ownership changes

All companies →

2025-02-20

Below 5%−1.30pt

NOMURA INTERNATIONAL PLC cut holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 4.54% from 5.84%, below the 5% threshold.

S100V9ZSFiler profile Original filing (PDF, Japanese)
2024-07-19

Decrease−0.69pt

NOMURA INTERNATIONAL PLC reduced holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 5.84% from 6.53%.

S100U2QJFiler profile Original filing (PDF, Japanese)
2024-04-19

Decrease−0.95pt

NOMURA INTERNATIONAL PLC reduced holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 6.53% from 7.48%.

S100TAVBFiler profile Original filing (PDF, Japanese)
2024-03-05

Increase+1.38pt

Nomura Asset Management Co., Ltd. raised holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 7.48% from 6.10%.

S100SZZIFiler profile Original filing (PDF, Japanese)
2023-07-06

Increase+0.97pt

Nomura Securities Co.,Ltd. raised holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 6.10% from 5.13%.

S100RCJSFiler profile Original filing (PDF, Japanese)
2023-04-06

New 5% stake

Nomura Securities Co.,Ltd. disclosed a 5.13% stake in JCR Pharmaceuticals Co.,Ltd. (4552), crossing the 5% reporting threshold.

S100QJV3Filer profile Original filing (PDF, Japanese)
2023-03-14

Below 5%−0.29pt

KISSEI PHARMACEUTICAL CO., LTD. cut holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 4.95% from 5.24%, below the 5% threshold.

S100QD5JFiler profile Original filing (PDF, Japanese)
2023-03-01

Decrease−1.02pt

KISSEI PHARMACEUTICAL CO., LTD. reduced holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 5.24% from 6.26%.

S100QA6ZFiler profile Original filing (PDF, Japanese)
2022-12-12

Decrease−1.31pt

KISSEI PHARMACEUTICAL CO., LTD. reduced holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 6.26% from 7.57%.

S100PS4UFiler profile Original filing (PDF, Japanese)
2022-09-12

Decrease−2.15pt

KISSEI PHARMACEUTICAL CO., LTD. reduced holdings in JCR Pharmaceuticals Co.,Ltd. (4552) to 7.57% from 9.72%.

S100P61UFiler profile Original filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
キッセイ薬品工業株式会社	2021-11-10 – 2023-03-07	-5,118,300	−3.94pt	¥1,809.53	¥1,705–1,928

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4552/trades.

5% filings

Large shareholding reports on 4552

Filed	Filer	Stake	Change	Stated purpose
2025-02-20	NOMURA INTERNATIONAL PLC	4.54%	−1.30pt	—
2024-07-19	NOMURA INTERNATIONAL PLC	5.84%	−0.69pt	—
2024-04-19	NOMURA INTERNATIONAL PLC	6.53%	−0.95pt	—
2024-03-05	Nomura Asset Management Co., Ltd.	7.48%	+1.38pt	—
2023-11-16	MEDIPAL HOLDINGS CORPORATION	22.46%	0.00pt	business alliance
2023-07-06	Nomura Securities Co.,Ltd.	6.10%	+0.97pt	—
2023-04-06	Nomura Securities Co.,Ltd.	5.13%	—	—
2023-03-14	KISSEI PHARMACEUTICAL CO.,LTD.	4.95%	−0.29pt	pure investment
2023-03-01	KISSEI PHARMACEUTICAL CO.,LTD.	5.24%	−1.02pt	pure investment
2023-01-23	KISSEI PHARMACEUTICAL CO.,LTD.	6.26%	0.00pt	pure investment

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: 1 issues
Book value: ¥705m
Sold in the year: — — issues
Bought in the year: — — issues
Mutual, both reports: 1
Held by listed cos.: 1

Holds	Book value	Shares vs. prior year	Mutual
Mochida Pharmaceutical Co.,Ltd. 4534	¥705m	0.0%	both reports

Held by: Mochida Pharmaceutical Co.,Ltd. 4534

Purposes, all holdings and mutual flags via /v1/companies/4552/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31

Shareholder	Shares	Ratio
株式会社メディパルホールディングス	29,131,000	23.83%
日本マスタートラスト信託銀行株式会社（信託口）	9,273,000	7.58%
フューチャーブレーン株式会社	8,711,000	7.12%
野村信託銀行株式会社（Ａ信託口）	5,498,000	4.49%
株式会社日本カストディ銀行（信託口）	5,169,000	4.22%
キッセイ薬品工業株式会社	4,918,000	4.02%
持田製薬株式会社	2,200,000	1.80%
ゴールドマン・サックス証券株式会社BNYM	1,527,000	1.24%
individual holder	1,500,000	1.22%
ＪＣＲファーマ従業員持株会	1,489,000	1.21%

U.S. funds holding 4552

SEC Form N-PORT, reports to 2026-07-31

19 U.S. funds held 2,912,200 shares worth $8.6m.

Fund	Shares	Value	% of fund	As of
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS	1,066,475	$3.2m	0.000%	2026-07-31
VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS	715,249	$2.0m	0.001%	2026-06-30
VANGUARD FTSE ALL-WORLD EX-US SMALL-CAP INDEX FUND VANGUARD INTERNATIONAL EQUITY INDEX FUNDS	303,500	$0.9m	0.007%	2026-07-31
Schwab International Small-Cap Equity ETF SCHWAB STRATEGIC TRUST	163,644	$0.5m	0.009%	2026-05-31
THE JAPANESE SMALL COMPANY SERIES DFA INVESTMENT TRUST CO	142,600	$0.4m	0.011%	2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4552
GET /v1/companies/4552/financials
GET /v1/companies/4552/details
GET /v1/companies/4552/segments
GET /v1/companies/4552/voting
GET /v1/companies/4552/tender-offers
GET /v1/companies/4552/indicators
GET /v1/companies/4552/earnings-releases
GET /v1/events?ticker=4552
GET /v1/companies/4552/trades         
GET /v1/companies/4552/cross-holdings 
GET /v1/companies/4552/brief

Plans from $9 a month · Documentation